Impact of Patent Expiry on Product Development in India

What happens when a ₹745 crore diabetes drug goes off-patent in India? The answer: 150+ new brands. Prices drop by 80–90%. And patients finally win. But here’s the twist—this isn’t just a story of cheaper drugs. It’s a masterclass in how Indian pharma works. Let’s unpack it: 1 | The Molecule Empagliflozin, a Type 2 diabetes drug in the SGLT2 inhibitor class, was once an innovator product. Patented. Premium. Restricted access. Now that the patent has expired, it’s open season—and nearly every major Indian pharma player has jumped in. 2 | The Gold Rush In just one month, the number of empagliflozin brands has doubled. Prices have plummeted from ₹50+ per unit to as low as ₹5–6. It’s classic Indian pharma: high-volume, low-margin, branded generics. 3 | Why This Matters Over 100 million Indians live with diabetes. In rural areas, the problem is growing faster than infrastructure can keep up. When access improves, so does adherence. A lower price can mean the difference between skipped doses and sustained care. 4 | But Quality Can’t Be a Casualty With 200+ generics flooding the market, quality surveillance becomes crucial. Not all “branded generics” are created equal—and the patient doesn’t always know which one meets the bar. This is where revised Schedule M comes in—India’s new mandate for Good Manufacturing Practices. But as the news reports, only 1% of small pharma companies have applied for compliance so far. 5 | The Balancing Act Innovators need reward for R&D. Generics need quality guardrails. Patients need access they can trust. Regulators need to move faster—but also smarter. So the real question isn’t just: how many brands entered the market? It’s: how many will stay, scale, and serve patients without compromising safety? As India redefines affordable care, we must remember—volume without vigilance is a risk we can’t afford. What’s your take: Can we keep quality intact while scaling access at this pace?

𝐑𝐮𝐬𝐬𝐢𝐚’𝐬 $150𝐌𝐧 𝐠𝐞𝐧𝐞𝐫𝐢𝐜 𝐎𝐳𝐞𝐦𝐩𝐢𝐜 𝐫𝐞𝐯𝐞𝐧𝐮𝐞 𝐜𝐨𝐮𝐥𝐝 𝐬𝐞𝐫𝐯𝐞 𝐚𝐬 𝐚𝐧 𝐚𝐧𝐜𝐡𝐨𝐫 𝐩𝐨𝐢𝐧𝐭 𝐟𝐨𝐫 𝐦𝐚𝐫𝐤𝐞𝐭𝐬 𝐰𝐡𝐞𝐫𝐞 𝐎𝐳𝐞𝐦𝐩𝐢𝐜 𝐢𝐬 𝐠𝐨𝐢𝐧𝐠 𝐨𝐟𝐟-𝐩𝐚𝐭𝐞𝐧𝐭.. Recently the Russian government granted #compulsorylicense to a local company #Geropharm to produce and sell the generic version of #Ozempic (#Semaglutide) locally. This license was granted by side-stepping the Semaglutide (Sema) patent, with scheduled expiry of 2031, & without the consent of the innovator #NovoNordisk. The license is actually a renewal & not a fresh grant. The first time this license was granted was in end 2023 for a year after #Novo announced that it will stop supplying Ozempic to Russian patients. While Geropharm is already selling in Russia, it has sought a compulsory license directly from Novo probably to broaden the scope of its commercialisation globally. As per industry estimates, in 2024 Gx Sema clocked about $140-150Mn annual sales in Russia, a market with 5Mn #diabetes #patients. Geropharm sold the drug at ~$50/month which was 24% cheaper than Novo’s Ozempic in the same mkt. Sema, marketed as Wegovy and Ozempic by Novo Nordisk, generated $25.4B in global sales in 2024, with Wegovy contributing $8.4B and Ozempic $17B. Now the Sema patent expiry in March'26 opens up 80 markets, including India, Canada, Brazil, creating a massive opportunity for #generic companies including Indian & Chinese players. As several companies prepare for launch in 2026, there are several decision factors to be addressed. Foremost being: ➡️ What is the competition pool looking like ➡️ How many markets will see generics immediately upon patent expiry ➡️ What’s the total demand in units & value ➡️ What would be a sustainable launch price for at least 1 year to begin with ➡️ What are market competitive CoGs for the product ➡️ Which API/Formulation players, or CDMOs hold the potential to manufacture at commercial scale and at competitive prices ➡️ How much share will Gx sema take from #Tirzepatide and how will Tirzepatide adjust itself In India, a major Diabetes and #Obesity market, recently #EliLilly launched its #Innovator Drug #Mounjaro (Tirzepatide) at INR 14K – 17.5K/month ($160 to $200) cost of treatment. While analysts are split between the decision of Gx Sema pricing at launch as some predict sharp fall in price by as much as 95% whereas others expect a minimal drop Vs Mounjaro’s price. However, everyone has a similar view on the huge demand opportunity and volume surge for the drug post launch. Recently #MorganStanley stated that GLP-1 adoption within the US reached just 2-3% of eligible population, whereas ex-US this adoption is barely 1%. Since established generics in diabetes have seen a 15% penetration rate earlier, this means a significant headroom for GLP-1s globally as well as in the soon-to-be-genericized markets. What’s your view about the upcoming Gx Semaglutide market?

💉 Zydus Group + Lupin Pharmaceuticals vs Novo Nordisk — a patent expiry that could reshape India’s obesity drug market. Most people see drug patents as a legal detail. But in pharma? It’s a multi-billion dollar turning point. A recent update caught my attention:
👉 Zydus Lifesciences and Lupin have partnered to launch a generic version of semaglutide in India. And this is happening just as the patent of Novo Nordisk’s blockbuster drug expires. 💡 What does this really mean? The moment a patent expires: : Expensive branded drugs → become affordable generics : Market shifts from monopoly → intense competition : Access expands to millions of new patients But here’s the part most people miss 👇 👉 This isn’t just about launching a drug.
👉 It’s about who captures the market FIRST. 🚀 My take:
In today’s pharma landscape,
the biggest winners aren’t just the innovators but the ones who play the timing game perfectly. Because here: ~ Speed = market share ~ Distribution = dominance ~ Partnerships = scale And this Zydus–Lupin move?
It’s exactly that. 📊 From a consulting lens, this raises key questions: - Who will dominate distribution in India? - How will companies balance low pricing vs profitability? - Will brand power survive when generics flood the market? Zooming out…
This isn’t just about one drug. It’s about a massive shift in the obesity & diabetes market — making it more competitive, more accessible, and far more strategic. As someone moving into consulting,
this is what excites me —Not just what companies do but when they do it, and how they scale it. 👉 Question that is raised : 
Do generics truly democratize healthcare…
or do they just trigger a race to the bottom on pricing? #Pharma #Healthcare #Consulting #Strategy #Generics #India #BusinessThinking

𝗜𝗻𝗱𝗶𝗮 𝘃𝘀 𝗨𝗦𝗔: 𝗦𝗲𝗺𝗮𝗴𝗹𝘂𝘁𝗶𝗱𝗲 𝗜𝘀 𝗮 𝗪𝗲𝗶𝗴𝗵𝘁-𝗟𝗼𝘀𝘀 𝗗𝗿𝘂𝗴 𝗶𝗻 𝗔𝗺𝗲𝗿𝗶𝗰𝗮 — 𝗕𝘂𝘁 𝗜𝗻 𝗜𝗻𝗱𝗶𝗮, 𝗜𝘁’𝘀 𝗮 𝗛𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲 𝗥𝗲𝘃𝗼𝗹𝘂𝘁𝗶𝗼𝗻 · · · · · The same molecule. Two completely different realities. Semaglutide — the active ingredient in Ozempic and Wegovy — is reshaping global healthcare. But how it is being accessed in India vs. the United States tells a far more important story than the drug itself. · · · · · 𝗧𝗵𝗲 𝗣𝗿𝗶𝗰𝗲 𝗚𝗮𝗽 𝗶𝘀 𝗦𝘁𝗮𝗴𝗴𝗲𝗿𝗶𝗻𝗴 In the US, semaglutide costs the equivalent of ₹1.16–1.47 lakh per month. In India, generics launched in March 2026 are now available from as little as ₹1,250 per month — that’s a price gap of up to 98%. Natco Pharma’s vial version launched at ₹1,290. Glenmark’s weekly dose starts at just ₹325. This is not a small difference. It is the difference between a drug that exists for the affluent and one that reaches 101 million diabetic patients. · · · · · 𝗪𝗵𝘆 𝗜𝗻𝗱𝗶𝗮 𝗠𝗼𝘃𝗲𝗱 𝗙𝗶𝗿𝘀𝘁 Semaglutide’s patent in India expired on March 20, 2026 — while the US patent remains protected until the 2030s. The moment it expired, 10+ Indian pharmaceutical companies launched generic versions: Sun Pharma, Dr. Reddy’s, Zydus, Glenmark, Lupin, Natco, Alkem. India’s generic drug industry, which already supplies 20% of the world’s off-patent medicines, was ready. Zero generic competitors exist in the US today. · · · · · 𝗧𝗵𝗲 𝗠𝗮𝗿𝗸𝗲𝘁 𝗢𝗽𝗽𝗼𝗿𝘁𝘂𝗻𝗶𝘁𝘆 India’s addressable diabetes base: 101 million patients. Market growth rate: 14.8% annually — nearly double the US rate of 8–10%. The Indian anti-obesity drug market, currently valued at ₹1,400 crore, is projected to grow nearly sixfold to ₹8,300 crore within a year of generic launches. Dr. Reddy’s alone is targeting 12 million semaglutide pens in its first year — and has expansion plans across 87 countries as patents expire globally. · · · · · 𝗧𝗵𝗲 𝗕𝗶𝗴𝗴𝗲𝗿 𝗟𝗲𝘀𝘀𝗼𝗻 This is what happens when a patent cliff meets a country called “the world’s pharmacy.” India isn’t just making a drug cheaper. It is demonstrating what healthcare access at scale actually looks like — and potentially reshaping the global GLP-1 market as other countries’ patents expire in the years ahead. The drug that costs $1,400/month in America may soon cost $14 in India. The implications are profound for patients, investors, and policymakers everywhere. · · · · · #Pharma #Semaglutide #GLP1 #Healthcare #India #Generics #Ozempic #Diabetes #DrugPricing #GlobalHealth #Investment #BusinessStrategy · · · · · 👇🏻 𝗦𝗵𝗮𝗿𝗲 𝘆𝗼𝘂𝗿 𝘁𝗵𝗼𝘂𝗴𝗵𝘁𝘀 𝗶𝗻 𝘁𝗵𝗲 𝗰𝗼𝗺𝗺𝗲𝗻𝘁𝘀! ♻️ 𝗥𝗲𝗽𝗼𝘀𝘁 𝘁𝗼 𝘀𝗵𝗮𝗿𝗲 𝘄𝗶𝘁𝗵 𝘆𝗼𝘂𝗿 𝗻𝗲𝘁𝘄𝗼𝗿𝗸. 𝗪𝗵𝗶𝗹𝗲 𝘆𝗼𝘂’𝗿𝗲 𝗵𝗲𝗿𝗲, 𝗜’𝗺 𝗔𝗱𝗮𝗺 𝗠𝗼𝘀𝘁𝗮𝗳𝗮! 𝗜𝗳 𝘆𝗼𝘂 𝗱𝗼𝗻’𝘁 𝗸𝗻𝗼𝘄 𝗺𝗲 𝗮𝗹𝗿𝗲𝗮𝗱𝘆 𝗮𝗻𝗱 𝘆𝗼𝘂 𝗲𝗻𝗷𝗼𝘆𝗲𝗱 𝘁𝗵𝗶𝘀 𝗽𝗼𝘀𝘁, 𝘄𝗵𝘆 𝗱𝗼𝗻’𝘁 𝘆𝗼𝘂 𝗴𝗶𝘃𝗲 𝗺𝗲 𝗮 𝗳𝗼𝗹𝗹𝗼𝘄?